TITLE

Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir

AUTHOR(S)
Reddy, David
PUB. DATE
April 2010
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Apr2010 Supplement 2, Vol. 65 Issue suppl_2, pii35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pandemic (H1N1) 2009 influenza is affecting countries in all five continents, with most cases so far having been reported in North and South America and Europe, and children and young adults being the most susceptible age groups. To date, the clinical course of disease is typically mild, with low hospitalization and mortality rates. Pandemic (H1N1) 2009 is susceptible to oseltamivir and, although few clinical data are yet available, current information suggests that treatment with oseltamivir appears to be beneficial. Only isolated cases of resistance to the drug have been reported to date, in keeping with the low frequency observed in clinical studies involving patients infected with seasonal influenza viruses. Current health authority guidelines recommend the use of oseltamivir in infected adults and children who have or are at elevated risk for severe disease, including pregnant women; use during the pandemic in infants <1 year has also been authorized in Europe and a number of other countries, including the USA and Canada. Before the onset of the current pandemic, F. Hoffmann-La Roche Ltd expanded annual production capacity for oseltamivir to 400 million treatment courses per year to meet anticipated demand. However, during an influenza pandemic, and despite increased production capabilities, resources are nonetheless likely to be initially in short supply. For this reason, Roche, in line with WHO recommendations, has advocated advance stockpiling of antivirals by governments as a pandemic preparedness measure. Between 2004 and December 2009, 350 million treatment courses were supplied to governments worldwide. Support for developing countries has been a priority. Roche has established a cluster of initiatives aimed at increasing access to Tamiflu for the world's developing economies, including, making donations to the WHO, establishing the Tamiflu Reserves Program (TRP) and sub-licensing and manufacturing contracts with local companies in Asia and Africa. Furthermore, Roche has published a document outlining how it would allocate limited supplies of Tamiflu during a pandemic, which are in line with WHO recommendations stating that ‘resources should be used to provide the maximum possible health benefit’. Roche is also offering support such as reprocessing of expiring capsule stocks (in development) and shelf-life extension to support governments in the management of their stockpiles. Clinical studies, either sponsored by or supported by Roche, are in progress. These trials are designed to investigate the effectiveness of oseltamivir in patients infected with the pandemic virus in greater depth, and include high-dose studies, assessment of natural and drug-induced resistance, and response to treatment in high-risk populations such as young infants, immunocompromised patients and the severely ill.
ACCESSION #
52860283

 

Related Articles

  • Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, South Korea. Hwajung Yi; Joo-Yeon Lee; Eun-Hye Hong; Mi-Seon Kim; Donghyok Kwon; Jang-Hoon Choi; Woo-Young Choi; Ki-Soon Kim; Jong-Koo Lee; Hee-Bok Oh; Chun Kang // Emerging Infectious Diseases;Dec2010, Vol. 16 Issue 12, p1938 

    To identify oseltamivir resistance, we analyzed neuraminidase H275Y mutations in samples from 10 patients infected with pandemic (H1N1) 2009 virus in South Korea who had influenza that was refractory to antiviral treatment with this drug. A neuraminidase 1117M mutation that might influence...

  • Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. Moss, Ronald B.; Davey, Richard T.; Steigbigel, Roy T.; Fang Fang // Journal of Antimicrobial Chemotherapy (JAC);Jun2010, Vol. 65 Issue 6, p1086 

    The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to the human population. While vaccines are the principal public health defence against influenza, rapid vaccine...

  • Alternative Therapeutic Options for Pandemic Influenza A H1N1. Tien, Pamela; Nieh, Jonathan; Song, Jessica C. // Infectious Disease Alert;Jan2010, Vol. 29 Issue 4, p39 

    The article discusses alternative therapeutic options for addressing pandemic influenza A H1N1. It notes that tests made on the pandemic influenza A H1N1 virus isolates have yielded results showing 100% resistance to certain antiviral agents as well as over 99% susceptibility rate to the...

  • Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infection in Two Summer Campers Receiving Prophylaxis -- North Carolina, 2009. Garrison, M.; Weldon, L.; Brantley, P.; Wolf, L.; Davies, M.; Maillard, J.-M.; Moore, Z.; Sheu, T.; Deyde, V.; Gubareva, L.; Fry, A. M.; Fleischauer, A.; Dailey, N. J. // MMWR: Morbidity & Mortality Weekly Report;9/11/2009, Vol. 58 Issue 35, p969 

    The article reports on two girls in a summer camp in North Carolina contacting influenza A(H1N1) virus resistant to oseltamivir, a neurominidase inhibitor commonly used for medication and chemoprophylaxis. In this case, the occurrence of an oseltamivir resistant A(H1N1) virus cannot be...

  • Developing Countries, Where Medical Care Systems Are Weak And Supplies.  // AirGuide Online.com;6/15/2009, p1 

    The article offers information on the strategy of the World Health Organisation (WHO) to deal with the global spread of swine flu. It reports that the WHO will focus on developing countries during its battle against the pandemic influenza, due to their problems of antiviral insufficiencies and...

  • Influenza humana: A(H1N1). Nota de actualidad. Angulo, Gustavo Barriga // Revista Mexicana de Patologia Clinica;abr-jun2009, Vol. 56 Issue 2, p77 

    No abstract available.

  • Effect of Vaccines and Antivirals during the Major 2009 A(H1N1) Pandemic Wave in Norway - And the Influence of Vaccination Timing. de Blasio, Birgitte Freiesleben; Iversen, Bj�rn G.; Tomba, Gianpaolo Scalia // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    To evaluate the impact of mass vaccination with adjuvanted vaccines (eventually 40% population coverage) and antivirals during the 2009 influenza pandemic in Norway, we fitted an age-structured SEIR model using data on vaccinations and sales of antivirals in 2009/10 in Norway to Norwegian ILI...

  • Effect of Vaccines and Antivirals during the Major 2009 A(H1N1) Pandemic Wave in Norway - And the Influence of Vaccination Timing. de Blasio, Birgitte Freiesleben; Iversen, Bjørn G.; Tomba, Gianpaolo Scalia // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    To evaluate the impact of mass vaccination with adjuvanted vaccines (eventually 40% population coverage) and antivirals during the 2009 influenza pandemic in Norway, we fitted an age-structured SEIR model using data on vaccinations and sales of antivirals in 2009/10 in Norway to Norwegian ILI...

  • Withholding flu drugs from seniors a new discussion item.  // Long-Term Living: For the Continuing Care Professional;Sep2009, Vol. 58 Issue 9, p10 

    The article reports on the suggestion of researchers from Italy's Bruno Kessler Foundation that the elderly should be the last in line to receive swine flu drugs. According to the researchers, giving antiviral drugs to older people would not decrease mortality and may even increase resistance....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics